Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 12/20 | 0.51 |
| ▸ | CTNNB1 | P35222 | 12/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30171240 | 0.92 | SETD7 (0.44) | BCL9CTNNB1PDE4BCCNT1CCNA2 | |
| SCHEMBL30392508 | 0.91 | CCNT1 (0.47) | BCL9CTNNB1PDE4BCCNT1CCNA2 | |
| SCHEMBL23456285 | 0.91 | BCL9 (0.55) | BCL9CTNNB1PDE4BROCK2PDE4A | |
| SCHEMBL23456284 | 0.91 | BCL9 (0.55) | BCL9CTNNB1PDE4BROCK2PDE4A | |
| SCHEMBL30171158 | 0.90 | BCL9 (0.51) | BCL9CTNNB1PARP1PDE4BCCNT1 | |
| SCHEMBL31205136 | 0.85 | PDE4B (0.46) | BCL9CTNNB1PARP1PDE4BROCK2 | |
| SCHEMBL30392229 | 0.83 | BCL9 (0.58) | BCL9CTNNB1PDE4BPDE4APDE4C | |
| SCHEMBL23456281 | 0.81 | SETD7 (0.49) | BCL9CTNNB1ROCK2 | |
| SCHEMBL23456282 | 0.81 | SETD7 (0.49) | BCL9CTNNB1ROCK2 | |
| SCHEMBL30171073 | 0.81 | BCL9 (0.63) | BCL9CTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12286422-B2 | Methods and compositions of 4-substituted benzoylpiperazine-1-substituted carbonyls as β-catenin/B-cell lymphoma 9 inhibitors | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2025-04-29 | — | — | US | disclosed |
| US-20230122912-A1 | Methods and Compositions of 4-Substituted Benzoylpiperazine-1-Substituted Carbonyls as Beta-Catenin/B-Cell Lymphoma 9 Imhibitors | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2023-04-20 | — | — | US | disclosed |
| US-11542254-B2 | Methods and composition of 4-substituted benzoylpiperazine-1-substituted carbonyls as beta-catenin/B-cell lymphoma 9 inhibitors | UNIVERSISITY OF UTAH RESEARCH FOUNDATION (US) | 2023-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542254-B2 | Methods and composition of 4-substituted benzoylpiperazine-1-substituted carbonyls as beta-catenin/B-cell lymphoma 9 inhibitors | BCL9, BCL9L, BCL3 | BCL9 1/4885CTNNB1 6/4885PARP1 803/4885 |
| US-12286422-B2 | Methods and compositions of 4-substituted benzoylpiperazine-1-substituted carbonyls as β-catenin/B-cell lymphoma 9 inhibitors | BCL9, BCL9L, BCL3 | BCL9 1/4885CTNNB1 6/4885PARP1 782/4885 |
| US-20230122912-A1 | Methods and Compositions of 4-Substituted Benzoylpiperazine-1-Substituted Carbonyls as Beta-Catenin/B-Cell Lymphoma 9 Imhibitors | BCL9, BCL9L, BCL3 | BCL9 1/4885CTNNB1 6/4885PARP1 870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.